# A Platform Study of Novel Immunotherapy Combinations in Participants With Previously Untreated, Advanced/Metastatic Non-Small-Cell Lung Cancer

Source: https://onco.cc/trials/nct05565378/  
OnCo record `nct05565378` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of Pembrolizumab and Dostarlimab in non-small-cell lung cancer, run by GlaxoSmithKline, active and no longer recruiting.

## Summary

A Platform Study of Novel Immunotherapy Combinations in Participants With Previously Untreated, Advanced/Metastatic Non-Small-Cell Lung Cancer is a phase 2 interventional study registered as NCT05565378 by GlaxoSmithKline, with 351 participants enrolled, started 2022-10-14 and due to reach its primary completion in 2026-11-09. Interventions recorded: Pembrolizumab, Dostarlimab, Belrestotug and Nelistotug.

## Fields

- Kind: Trial
- Status: active
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT05565378
- Phase: 2
- Setting: A Phase 2, Randomized, Open-label, Platform Study Utilizing a Master Protocol to Evaluate Novel Immunotherapy Combinations in Participants With Previously Untreated, Locally Advanced/Metastatic, Programmed Death Ligand 1-Selected Non-Small-Cell Lung Cancer
- Sponsor: GlaxoSmithKline
- Enrolled: 351

## Sources

- ClinicalTrials.gov NCT05565378: https://clinicaltrials.gov/study/NCT05565378

## Connected records

- cancers: [Non-small-cell lung cancer](https://onco.cc/cancers/nsclc/)
- drugs: [Dostarlimab](https://onco.cc/drugs/dostarlimab/), [Pembrolizumab](https://onco.cc/drugs/pembrolizumab/)
- companies: [GSK](https://onco.cc/companies/gsk/)

---
JSON: https://onco.cc/api/v1/entities/nct05565378.json